Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReposMBZ in Advanced GI Cancer
NCT03628079Phase 2Terminated
- Sponsor
- Repos Pharma
- Start
- May 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mebendazole in gastrointestinal cancer and cancer of unknown primary origin (CUP), sponsored by Repos Pharma. Primary endpoints: Incidence of adverse events (AEs) probably or possibly related to ReposMBZ up to 20 weeks, Changes in plasma Albumin over time up to 20 weeks and 12 more. Started May 2018; status: terminated.
02
Drugs
mebendazole
03
Conditions
gastrointestinal cancercancer of unknown primary origin (CUP)
Beyond the preview
Go deeper on NCT03628079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03628079.